Journal of Neural Transmission

, Volume 120, Issue 2, pp 347–348

Is there room for non-dopaminergic treatment in Parkinson disease?

Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Abstract

Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

Keywords

Parkinson disease Levodopa Non-dopaminergic drugs Non-motor symptoms 

References

  1. Birkmayer W, Birkmayer G, Lechner H, Riederer P (1983) DL-3,4-threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm 58(3–4):305–313PubMedCrossRefGoogle Scholar
  2. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL (2009) History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73(20):1670–1676. doi:10.1212/WNL.0b013e3181c1ded6 PubMedCrossRefGoogle Scholar
  3. Chung KA, Lobb BM, Nutt JG, Horak FB (2010) Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 75(14):1263–1269. doi:10.1212/WNL.0b013e3181f6128c PubMedCrossRefGoogle Scholar
  4. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan Y, Xu H, Shaw DE (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 108(32):13118–13123. doi:10.1073/pnas.1104614108 PubMedCrossRefGoogle Scholar
  5. Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 70:477–484PubMedCrossRefGoogle Scholar
  6. Kaufmann H (2008) L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auto Res: Off J Clin Auto Res Soc 18(Suppl 1):19–24. doi:10.1007/s10286-007-1002-2 CrossRefGoogle Scholar
  7. Mathias CJ (2008) L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auto Res: Off J Clin Auto Res Soc 18(Suppl 1):25–29. doi:10.1007/s10286-007-1005-z CrossRefGoogle Scholar
  8. McFarland K, Price DL, Bonhaus DW (2011) Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behav Pharmacol 22(7):681–692. doi:10.1097/FBP.0b013e32834aff98 PubMedCrossRefGoogle Scholar
  9. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol 35(4):881–892. doi:10.1038/npp.2009.176 CrossRefGoogle Scholar
  10. Ogawa N, Yamamoto M, Takayama H (1985) L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson’s disease. J Med 16(5–6):525–534PubMedGoogle Scholar
  11. Ouattara B, Gasparini F, Morissette M, Gregoire L, Samadi P, Gomez-Mancilla B, Di Paolo T (2010) Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 113(3):715–724. doi:10.1111/j.1471-4159.2010.06635.x PubMedCrossRefGoogle Scholar
  12. Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010) A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39(3):352–361. doi:10.1016/j.nbd.2010.05.001 PubMedCrossRefGoogle Scholar
  13. Sheffler DJ, Gregory KJ, Rook JM, Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors. Adv Pharmacol 62:37–77. doi:10.1016/B978-0-12-385952-5.00010-5 PubMedCrossRefGoogle Scholar
  14. Yarnall A, Rochester L, Burn DJ (2011) The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord: Off J Mov Disord Soc 26(14):2496–2503. doi:10.1002/mds.23932 CrossRefGoogle Scholar
  15. Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic l-DOPA therapy in advanced Parkinson’s disease. Adv Neurol 69:541–544PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  1. 1.Muhammad Ali Parkinson Center, Barrow Neurological InstituteSt. Joseph’s Hospital and Medical CenterPhoenixUSA

Personalised recommendations